Fredun Pharmaceuticals Ltd
BSE:539730
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Fredun Pharmaceuticals Ltd
BSE:539730
|
IN |
|
Code Green Apparel Corp
OTC:CGAC
|
US |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
US |
|
Cascades Inc
TSX:CAS
|
CA |
|
Yealink Network Technology Co Ltd
SZSE:300628
|
CN |
|
Asia-Pacific Strategic Investments Ltd
SGX:5RA
|
SG |
Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd. engages in the manufacture and sale of pharmaceuticals, neutraceuticals, herbal and dietary supplements. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2016-03-17. The firm is primarily engaged in the business of pharmaceuticals and healthcare. The company operates through pharmaceutical formulation segment. The company offers a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. The company is also engaged in the manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with animal healthcare products. The firm primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.
Fredun Pharmaceuticals Ltd. engages in the manufacture and sale of pharmaceuticals, neutraceuticals, herbal and dietary supplements. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2016-03-17. The firm is primarily engaged in the business of pharmaceuticals and healthcare. The company operates through pharmaceutical formulation segment. The company offers a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs) and narcotics. The company is also engaged in the manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with animal healthcare products. The firm primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.
Strong growth: Q3 revenue was INR 160.92 crores, up 57% YoY, with 9M revenue INR 426 crores, up 48% YoY — management highlighted broad-based traction across recently launched brands.
Margins improving: Q3 EBITDA INR 26.34 crores (EBITDA margin 16%, +384 bps YoY); 9M EBITDA INR 65.66 crores (margin 15%, +237 bps) and net profit nearly doubled YoY.
Cash / funding: Management said there is no immediate need for additional fundraising over the next 12–18 months; recent QIP proceeds will be used to reduce working capital pressure.
Business mix shift: Management reiterated a strategic shift toward “new‑age” businesses (mobility, pet care, dermaceutics, nutraceuticals) with an objective that ~51% of revenue be from new‑age by 2029/2030.
Guidance (segmented): Legacy (vintage) business guidance 12–18% CAGR for the next 5–7 years; new‑age business expected to grow ~20–25% annually.
Working capital dynamics: Trade receivables are lumpy by quarter; management noted receivables have declined materially from peak levels and QIP funds will ease finance costs over next few quarters.
Operational approach: New‑age businesses will be increasingly asset‑light with greater use of third‑party manufacturers; certain high‑margin product lines (dermaceutics, pet care) should boost margins as they scale.
